Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment

Launched by CHENGDU SUNCADIA MEDICINE CO., LTD. · Nov 28, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called HRS-5965 for patients with a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). The study is aimed at individuals who are still experiencing anemia (low red blood cell count) even after receiving another treatment called a C5 complement inhibitor for at least six months. To participate, patients must be at least 18 years old and have a confirmed diagnosis of PNH, with specific criteria regarding their blood health. The trial is open to both men and women and is currently recruiting participants.

If eligible, patients will take HRS-5965 capsules over a treatment period of 24 weeks, following an initial 8-week screening phase. Participants will be monitored throughout the study to ensure their safety and to assess how well the treatment works. There are certain health conditions and recent treatments that may prevent someone from joining the trial, so it’s important for potential participants to discuss their medical history with the research team. Overall, this study aims to provide hope for those struggling with anemia related to PNH by testing a potentially effective new treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Understand the specific process of the experiment, voluntarily participate in this experiment, and sign a written informed consent form.
• • 2. Age ≥18 on the day of signing the informed consent, regardless of gender
• • 3. It was confirmed to be PNH during screening, and the clone size of red blood cells or granulocytes was detected by flow cytopy \>10%
• • 4. Stable use of C5 complement inhibitor ikuzumab/covalimab for the first 6 months of random treatment
• • 5. The average hemoglobin level of at least two tests in 4 months before screening \< 10 g/dL
• • 6. The average hemoglobin level of two tests in the central laboratory during screening \< 10 g/dL
• • 7. Inoccution of Neisseris meningitis and Streptococcus pneumoniae vaccine at least 2 weeks before the first administration of HRS-5965; if HRS-5965 treatment must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination.
• • 8. Male and female subjects with fertility must agree to adopt efficient contraceptive measures with their partners within 30 days from the signing of the informed consent form to the last administration, and have no family planning and no sperm/egg donation.
• Exclusion Criteria:
• • 1. In addition to C5 complement inhibitors (ikuzuzumab/covalimamab), those who have participated in clinical trials of any other drug or medical device within 1 month before and are expected to have a residual effect of experimental treatment (judged by researchers), or those who were still in the follow-up period of a clinical trial or the 5 half-life of the experimental drug before screening Inside (whichever is longer)
• • 2. Known or suspected hereditary or acquired complement deficiency
• • 3. Currently active primary or secondary immunodeficiency
• • 4. Those who have a history of splenectomy or plan to perform surgery during the trial
• • 5. History of bone marrow/hematopoietic stem cells or solid organ transplantation
• • 6. Diagnosed malignant tumors in the past 5 years
• • 7. There is laboratory evidence for patients with bone marrow failure during screening
• • 8. History of infection with pod bacteria (such as Neisseris meningitis, Streptococcus pneumoniae, etc.)
• • 9. There is or is suspected of systemic active bacteria, virus or fungal infection 2 weeks before the first administration of HRS-5965 (according to the researcher's judgment)
• • 10. Fever occurs within 1 week before the first administration of HRS-5965 (body temperature ≥38 ℃)
• • 11. Human immunodeficiency virus (HIV) infection
• • 12. Hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) are positive during screening, or abnormal liver function test during screening
• • 13. Use any of the following drugs, unless there is a stable treatment plan before screening: a) erythropoietin (ESA), hypoxic-inducing factor proaminoyl hydroxylase inhibitor (HIF-PHI) or immunosuppressant for at least 8 weeks b) Systemic use of glucocorticoids (≤15 mg/day Prednisone or equivalent doses of glucocorticoids) at least 4 weeks c) Vitamin K antagonists (such as warfarin) have a stable international standardized ratio (INR) at least 4 weeks d) Low molecular weight heparin, oral anticoagulants such as aspirin, rvaroxaban, apifloxaban, etc. at least 4 weeks e) Iron supplements , vitamin B12, folic acid or androgen for at least 4 weeks
• • 14. During screening, there are serious concurrent diseases, such as severe kidney disease (such as eGFR\<30 mL/min/1.73 m2, dialysis), advanced heart disease (such as NYHA level IV), severe lung disease such as pulmonary hypertension (WHO level IV) or liver disease (such as active hepatitis), etc. , judged by the researcher that it is not suitable to participate in the researcher
• • 15. Any medical condition determined by the researcher that it may affect the patient's participation in the trial, chronic anemia or unstable thrombosis events that may exist for other causes, and other conditions judged by the researcher to be unsuitable for participation in the trial
• • 16. Those who are suspected of being allergic to experimental drugs or any ingredient in experimental drugs
• • 17. Screening positive blood pregnancy test and breastfeeding women at the time of the visit